Global Leukemia Therapeutics Treatment Market Set for Rapid Growth And Trend, by 2025
Commercially available drug in the market for the treatment of leukemia includes Gleevec, Bosulif, Sprycel, Iclusig and others. Drugs which are in clinical trials expected to launch in the marketwithin next few (3 to 5)years include Bosutinib, Omapro, ga101/rg7159, Vidaza, Dacogen, Midostaurin, Vosaroxin, Quizartinib, Graspa, Marqibo.
The global market for leukemia treatment can be segmented as follows:
Based on the developmental and progression rate
Request to Sample Report - https://www.futuremarketinsights.com/reports/sample/rep-gb-421
Chronic leukemia is a type of blood cancer caused by uncontrolled growth of the WBC cells in our body. Chronic leukemia is a type of myeloproliferative disease which is characterized by the chromosomal translocation. Patients suffering from chronic leukemia show increased susceptibility to bacterial infections, thrombocytopenia and anemia and may also have enlarged spleen which causes pain on the left side. Incidence rate of chronic leukemia is high in men and is the second most common type of cancer occurring in male adults. Women who are above 50 years in age are expected to suffer from this chronic disease. Treatment for chronic leukemia depends on the phase of the disease that can be chronic, accelerated or the blast phase and the treatment for chronic leukemia includes chemotherapy, stem cell transplants and biologic therapies.
Acute myeloid leukemia develops at a speedy pace and is found in the blood and bone marrow. In the disease process, immature blood cells are present in the bone marrow. Symptoms found in patients due to the disease are flu, loss of weight, body ache, body pain and spots on skin.Treatment for acute leukemia includes chemotherapy, stem cell transplants and biologic therapies.
About 90% of the leukemia cases occur in the middle age and progresses with the aging. Therefore, leukemia therapeutics market is poised to grow with the rise in aging population and increasing incidences of leukemia. Drugs such as Bosulif, Gleevec, Sprycel andIclusigare commercially available for the treatment of leukemia. Gleevec was the first leukemia drug introduced in 2001, since then there has been a revolutionary change in the quality life of patients as compared to the former chemotherapy drugs.Globally the numbers of elderly people, 60 years and above are growing and it is expected that this age group will cross the 2 billion mark in 2050 stated by United Nations Population Division. Hence the leukemia therapeutics market will also grow significantly.However adverse event (cytotoxic) associated with nearly all kinds of leukemia therapeutics treatment might restrict the global market demand of leukemia therapeutics market.
Request Report TOC @ https://www.futuremarketinsights.com/toc/rep-gb-421
North America dominates the global market for leukemia therapeutics treatment due to high prevalence rate of leukemia (acute, chronic) and extensive technological advancement (diagnosis) in this region. Europe represents the second largest market share due to its large geriatric population base. In addition Asia-Pacific and RoW hold the third and fourth position in the global leukemia therapeutics market respectively due to less prevalence rate of leukemia and lack of proper healthcare facilities in few Asian and African countries.
North America accounted for 62% sales of leukemia drugs in the therapeutics market during 2010 followed by Europe and Asia Pacific. Leukemia therapeutics market will grow significantlyand the total growth will depend on pipeline products and metabolic inhibitors, a tyrosine kinase receptor FLT -3 of Novartis and some other capable molecules, improving the therapeutics market.
Major market playerscontributing the global market share of leukemia therapeutics treatment includes Ambit Biosciences Corporation, AriadPharmaceuticals,Inc., Biogen Idec, Inc., Novartis Pharmaceuticals, Bristol-Myers Squibb, Pfizer and others.
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Leukemia Therapeutics Treatment Market Set for Rapid Growth And Trend, by 2025 here
News-ID: 940175 • Views: 184
More Releases from Future Market Insights
How Changing Dynamics of Cable Testing Market are Reflecting on Growth Strategie …
Global Cable Testing Market: Introduction The cost of the substitution of cables that are concealed is very high. Faults in the cable, bending, kinking, and crushing, are not always visible, which has created the requirement for cable testing. Thus, cable testing helps check the cable functionality, cable quality, and cable conformity. Several times, cable testing by visual inspection is an effective way of identifying the actual problem before it causes any
How Transformative Trends in Self-Organising Network Market are Molding Strategi …
Self-Organising Network: Introduction With accelerated advancements and increasing complexities in the radio network technologies, such as those utilised for the development of LTE and 5G networks, which are used for planning, management, configuration, healing and optimisation, are required to be automated to facilitate efficiency. At present, suppliers are offering self-organising networks that possess the ability to offer optimum performance. Self-organising networks are use cases that perform network governance, including network planning,
Mining Vehicle AC Kits Market: Exploring the Impact of Trends on Strategies of K …
Mining Vehicle AC Kits Market: Introduction Cabin space in mining equipment has become more sophisticated in the recent past. The installation of mining vehicle AC kits has evolved from an optional feature to a necessary feature. Mining equipment manufacturers have made advancements in technology related to efficiency, performance and cost of air conditioning systems in order to make them affordable and economical to enable low-budget and compact installations without compromising on
Key Factors to Fuel Growth of the Talent Acquisition & Staffing Technology and S …
With the growing importance of recruiting and retaining top talent effectively and efficiently, smart hiring processes are the need of the hour. It is about time organisations move beyond merely scrutinising resumes. Salaries and benefits are important factors, but adopting ways that would make candidates an important part of the hiring process will attract the best talent. Studies reveal that due to discrepancies in existing Applicant Tracking Systems (ATS), hiring
More Releases for Leukemia
Juvenile Myelomonocytic Leukemia Therapeutics- Pipeline Analysis 2018
Juvenile myelomonocytic leukemia is a rare disease that occurs mostly in the children who are under four years of age. The abnormal growth of the monocytes results in the accumulation of monocytes in the bone marrow. Download the sample report @ https://www.pharmaproff.com/request-sample/1116 This leads to improper functioning of the bone marrow. The actual cause of juvenile myelomonocytic leukemia is still unknown; however, mutation in the RAS gene is observed in patients
Acute Myeloid Leukemia Market Growth by 2021
Acute Myeloid Leukemia (AML) is classed as an orphans disease. AML is a rare but a severe disease and is a most common leukemia. It is primarily a disease of the elderly, with an average age of diagnosis of approximately 66. AML results from the acquired changes in the DNA of a developing marrow cell. The marrow cells get converted into the leukemic cells, multiplies into 11 billion or more.
Acute Leukemia Therapeutics Pipeline Analysis
Acute leukemia is also known as cancer of blood cells in which immature blood cells modify into cancer cells. The disease arises from bone marrow and causes formation of numerous large blood cells. Leukemia is categorized into five different types namely acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and hairy cell leukemia. Leukemia can produce be symptoms such as fever, recurrent nosebleeds, bone pain, swollen
Leukemia Therapeutics Market – Global Industry Insights, 2025
Leukemia is a cancer of blood cells and therefore, are occasionally referred to as ‘blood cancer’. Most blood cells are formed in the bone marrow. In leukemia, undeveloped blood cells become cancer. Leukemia can be either acute or chronic. Acute leukemia is a fast growing cancer, which usually gets worse rapidly. Chronic leukemia is a slow growing cancer, which gets worse slowly over time period. The treatment and diagnosis of
Acute Lymphoblastic Leukemia (ALL) Market grows with high incidence of acute lym …
Acute lymphoblastic leukemia (ALL) is a cancer of white blood cells called as lymphocytes in bone marrow. It is a malignant disease in which early precursor lymphoid cells proliferate and replace the normal hematopoietic cells of bone marrow. ALL is the most common type of cancer in children. There is overproduction of lymphoblasts in the bone marrow when a person suffers from ALL that continuously multiply, damaging the bone marrow
New dynamics in monitoring diagnostics in leukemia
Dresden/Germany Diagnosis leukemia and stem cell transplantation The diagnosis "leukemia" for patients means to undergo several stressful therapeutic interventions. If chemotherapy is not effective, stem cell transplantation mostly is the last chance for healing. However, a sudden graft rejection or disease relapse can always occur despite the successful transfer of the hematopoietic stem cells from donor to recipient. Therefore, the regular quantitative assessment of the donor and recipient cell-portion in the blood